Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Oct 21, 2018 9:56am
153 Views
Post# 28842931

More assertive...

More assertive...April 2018, Financial PressRelease...Genenews said (Quote) Test volume was essencially '' Flat '' (End of Quote).

May 2018, Financial PressRelease... Genenews said (Quote) Test volume is '' Expected '' to grow (End of Quote).

All of a sudden in Aug 2018 Financial PressRelease the wording has become more assertive.

Genenews said (Quote) Q3 has started with a bang in July with test volume up 40%, cash receips from our billing early in Q3 showing the increases we have been expecting, and incremental(increase) testing with high risk population, as well as the AIM reps beginning (End of Quote).

First time in the last few years that Genenews has positive grow in tests volume.

In Aug 2018 AIM Laboratories big distribution network has started to sell Genenews multiple cancer tests.
In Aug & Sept 2018 we should see an even bigger grow in test volume (over 40%).
These 3 months consecutive grow in tests volume will appear in the next financial.

The assertive wording in the last financial indicate that Genenews is getting closer and closer to that very first green positive financial report.

Never underestimate the impact of the first time green profit in a pharmaceutical company, even a very small green profit will wake-up the market to the huge potential of Genenews innovative cancer tests.
Bullboard Posts